Supplemental material
Open access
0
Views
0
CrossRef citations to date
0
Altmetric
Report
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
Patrizia Murera Anaveon AG, Basel, SwitzerlandCorrespondence[email protected]
View further author information
, View further author information
Barbara Brannettib Novartis Institutes for BioMedical Research, Cambridge, MA, USAView further author information
, Jean-Michel Rondeauc Novartis Institutes for Biomedical Research, Basel, SwitzerlandView further author information
, Laetitia Petersena Anaveon AG, Basel, SwitzerlandView further author information
, Nicole Eglia Anaveon AG, Basel, SwitzerlandView further author information
, Simone Poppc Novartis Institutes for Biomedical Research, Basel, SwitzerlandView further author information
, Catherine Regnierc Novartis Institutes for Biomedical Research, Basel, SwitzerlandView further author information
, Kirsten Richtera Anaveon AG, Basel, SwitzerlandView further author information
, Andreas Katopodisa Anaveon AG, Basel, SwitzerlandView further author information
& Christoph Hubera Anaveon AG, Basel, SwitzerlandCorrespondence[email protected]
View further author information
show allView further author information
Article: 2381891
|
Received 07 Mar 2024, Accepted 15 Jul 2024, Published online: 23 Jul 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.